Cargando…

Development of TACE Refractoriness Scores in Hepatocellular Carcinoma

Purpose: To identify the independent risk factors for transarterial embolization (TACE) refractoriness and to develop a novel TACE refractoriness score and nomogram for predicting TACE refractoriness in patients with hepatocellular carcinoma (HCC). Methods: Between March 2006 and March 2016, HCC pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Li, Yu, Chen-Xi, Zhong, Bin-Yan, Zhu, Hai-Dong, Jin, Zhi-Cheng, Zhu, Guang-Yu, Zhang, Qi, Ni, Cai-Fang, Teng, Gao-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109267/
https://www.ncbi.nlm.nih.gov/pubmed/33981722
http://dx.doi.org/10.3389/fmolb.2021.615133
_version_ 1783690218344284160
author Chen, Li
Yu, Chen-Xi
Zhong, Bin-Yan
Zhu, Hai-Dong
Jin, Zhi-Cheng
Zhu, Guang-Yu
Zhang, Qi
Ni, Cai-Fang
Teng, Gao-Jun
author_facet Chen, Li
Yu, Chen-Xi
Zhong, Bin-Yan
Zhu, Hai-Dong
Jin, Zhi-Cheng
Zhu, Guang-Yu
Zhang, Qi
Ni, Cai-Fang
Teng, Gao-Jun
author_sort Chen, Li
collection PubMed
description Purpose: To identify the independent risk factors for transarterial embolization (TACE) refractoriness and to develop a novel TACE refractoriness score and nomogram for predicting TACE refractoriness in patients with hepatocellular carcinoma (HCC). Methods: Between March 2006 and March 2016, HCC patients who underwent TACE monotherapy as initial treatment at two hospitals formed the study cohort and validation cohort. The criteria of TACE refractoriness followed the Japan Society of Hepatology 2014 version of TACE refractoriness. In the study cohort, the independent risk factors for TACE refractoriness were identified, and TACE refractoriness score and nomogram were then developed. The accuracy of the systems was validated externally in the validation cohort. Results: In total, 113 patients from hospital A formed the study cohort and 122 patients from hospital B formed the validation cohort. In the study cohort, 82.3% of the patients (n = 93) developed TACE refractoriness with a median overall survival (OS) of 540 days (95% CI, 400.8–679.1), and the remaining 20 patients in the TACE-non-refractory group had a median OS of 1,257 days (95% CI, 338.8–2,175.2) (p = 0.019). The median time for developing TACE refractoriness was 207 days (95% CI, 134.8–279.2), and a median number of two TACE procedures were performed after refractoriness developed. The independent risk factors for TACE refractoriness were the number of tumors and bilobular invasion of HCC. TACE refractoriness scores <3.5 indicated a lower incidence of TACE refractoriness, whereas scores >3.5 points indicated a higher incidence (p < 0.001). In the validation cohort, 77.9% of the patients (n = 95) developed TACE refractoriness with a median OS of 568 days (95% CI, 416.3–719.7), and a median OS of 1,324 days was observed in the TACE-non-refractory group (n = 27; 95% CI, 183.5–2,464.5). Conclusions: TACE refractoriness impairs the OS of HCC patients. The number of tumors and bilobular invasion status were independent risk factors for TACE refractoriness. The TACE refractoriness score can be an effective tool and easy approach to predict the risk of TACE refractoriness status.
format Online
Article
Text
id pubmed-8109267
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81092672021-05-11 Development of TACE Refractoriness Scores in Hepatocellular Carcinoma Chen, Li Yu, Chen-Xi Zhong, Bin-Yan Zhu, Hai-Dong Jin, Zhi-Cheng Zhu, Guang-Yu Zhang, Qi Ni, Cai-Fang Teng, Gao-Jun Front Mol Biosci Molecular Biosciences Purpose: To identify the independent risk factors for transarterial embolization (TACE) refractoriness and to develop a novel TACE refractoriness score and nomogram for predicting TACE refractoriness in patients with hepatocellular carcinoma (HCC). Methods: Between March 2006 and March 2016, HCC patients who underwent TACE monotherapy as initial treatment at two hospitals formed the study cohort and validation cohort. The criteria of TACE refractoriness followed the Japan Society of Hepatology 2014 version of TACE refractoriness. In the study cohort, the independent risk factors for TACE refractoriness were identified, and TACE refractoriness score and nomogram were then developed. The accuracy of the systems was validated externally in the validation cohort. Results: In total, 113 patients from hospital A formed the study cohort and 122 patients from hospital B formed the validation cohort. In the study cohort, 82.3% of the patients (n = 93) developed TACE refractoriness with a median overall survival (OS) of 540 days (95% CI, 400.8–679.1), and the remaining 20 patients in the TACE-non-refractory group had a median OS of 1,257 days (95% CI, 338.8–2,175.2) (p = 0.019). The median time for developing TACE refractoriness was 207 days (95% CI, 134.8–279.2), and a median number of two TACE procedures were performed after refractoriness developed. The independent risk factors for TACE refractoriness were the number of tumors and bilobular invasion of HCC. TACE refractoriness scores <3.5 indicated a lower incidence of TACE refractoriness, whereas scores >3.5 points indicated a higher incidence (p < 0.001). In the validation cohort, 77.9% of the patients (n = 95) developed TACE refractoriness with a median OS of 568 days (95% CI, 416.3–719.7), and a median OS of 1,324 days was observed in the TACE-non-refractory group (n = 27; 95% CI, 183.5–2,464.5). Conclusions: TACE refractoriness impairs the OS of HCC patients. The number of tumors and bilobular invasion status were independent risk factors for TACE refractoriness. The TACE refractoriness score can be an effective tool and easy approach to predict the risk of TACE refractoriness status. Frontiers Media S.A. 2021-03-26 /pmc/articles/PMC8109267/ /pubmed/33981722 http://dx.doi.org/10.3389/fmolb.2021.615133 Text en Copyright © 2021 Chen, Yu, Zhong, Zhu, Jin, Zhu, Zhang, Ni and Teng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Chen, Li
Yu, Chen-Xi
Zhong, Bin-Yan
Zhu, Hai-Dong
Jin, Zhi-Cheng
Zhu, Guang-Yu
Zhang, Qi
Ni, Cai-Fang
Teng, Gao-Jun
Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
title Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
title_full Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
title_fullStr Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
title_full_unstemmed Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
title_short Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
title_sort development of tace refractoriness scores in hepatocellular carcinoma
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109267/
https://www.ncbi.nlm.nih.gov/pubmed/33981722
http://dx.doi.org/10.3389/fmolb.2021.615133
work_keys_str_mv AT chenli developmentoftacerefractorinessscoresinhepatocellularcarcinoma
AT yuchenxi developmentoftacerefractorinessscoresinhepatocellularcarcinoma
AT zhongbinyan developmentoftacerefractorinessscoresinhepatocellularcarcinoma
AT zhuhaidong developmentoftacerefractorinessscoresinhepatocellularcarcinoma
AT jinzhicheng developmentoftacerefractorinessscoresinhepatocellularcarcinoma
AT zhuguangyu developmentoftacerefractorinessscoresinhepatocellularcarcinoma
AT zhangqi developmentoftacerefractorinessscoresinhepatocellularcarcinoma
AT nicaifang developmentoftacerefractorinessscoresinhepatocellularcarcinoma
AT tenggaojun developmentoftacerefractorinessscoresinhepatocellularcarcinoma